地佐辛在神经外科术后镇痛的应用体会

目的：探讨地佐辛用于神经外科患者术后镇痛的效果和安全性。方法：将64例ASAⅠ～Ⅱ级行神经外科手术患者随机分为两组,术后均以静脉自控镇痛（PCIA）,其中A组（34例）用地佐辛,B组（30例）用舒芬太尼,观察两组镇痛、镇静效果及不良反应。结果：术后4 h、8 h、12 h、24 h视觉模拟评分（VAS）和不良反应发生率A组明显低于B组（P〈0.05）,Ramsay评分明显高于B组（P〈0.05）。结论：地佐辛用于神经外科患者术后镇痛确切,不良反应少。     

The Potential Value of Preoperative MRI Texture and Shape Analysis in Grading Meningiomas: A Preliminary Investigation

OBJECT: Preoperative knowledge of meningioma grade is essential for planning treatment and surgery. The purpose of this study was to investigate the diagnostic value of MRI texture and shape analysis in grading meningiomas. METHODS: A surgical database was reviewed to identify meningioma patients who had undergone tumor resection between January 2015 and December 2016. Preoperative MR images were retrieved and analyzed. Texture and shape analysis was conducted to quantitatively evaluate tumor heterogeneity and morphology. Three machine learning classifiers were trained with these features to build classification models. The performance of the features and classification models was assessed. RESULTS: A total of 131 patients were included in this study: 21 with high-grade meningiomas and 110 with low-grade meningiomas. Three texture features were selected: Horzl_RLNonUni, S(2,2)SumOfSqs, and WavEnHL_s-3; three shape features were selected: GeoFv, GeoW4, and GeoW5b. The Mann–Whitney test indicated that all six features were significantly different between high-grade and low-grade meningiomas. AUC values were generally greater than 0.50 (range, 0.73 to 0.88). Sensitivities and specificities ranged from 47.62% to 90.48% and 69.09% to 96.36%, respectively. Among the nine classification models obtained, the one built by training the SVM classifier with all six features achieved the best performance, with a sensitivity, specificity, diagnostic accuracy, and AUC of 0.86, 0.87, 0.87, and 0.87, respectively. CONCLUSIONS: Texture and shape analysis, especially when combined with a SVM classifier, can provide satisfactory performance in the preoperative determination of meningioma grade and is thus potentially useful for clinical application.     

锁骨下静脉穿刺置管术在神经外科重症患者的应用的临床效应 （附300 例病例报告）

目的:分析探讨锁骨下静脉穿刺置管术在重症神经外科疾病中的应用的临床效应。方法:选择锁骨下静脉,首选右侧,如果穿刺右侧失败改为左侧。穿刺成功后用扩张器扩皮,最后顺导丝置入导管,根据患者身高置管长度为12～15 cm,局部缝合固定,外敷纱布封闭或用一次性贴膜封闭。静脉留置管接三通静脉输液管。结果:286例首次穿刺右侧成功282例,4例失败后改选左侧成功。静脉导管留置时间最短3天,最长45天,留置时间平均为18天。结论:锁骨下静脉穿刺置管术在神经外科中抢救治疗重症患者是十分便利、有效的措施。锁骨下静脉穿刺置管术较其他深静脉穿刺置管如股静脉、颈内静脉和颈外静脉穿刺置管术及PICC相比较,更利于护理并具有费用低廉的优点。其方便、有效、经济的特点十分利于临床应用。     

关于在神经外科实习教学中采用Web-CPBL教学模式的探讨

在医学生临床实习带教过程中,神经外科实习教学由于其教学内容具有专业性强、信息量大、知识更新快的特点,与其它专业相比更具难度,教学效果往往难达到预期水平。Web-CPBL教学模式,是将传统的PBL教学理念与网络信息技术有机融合,延伸和发展出的一种新型教学模式。在神经外科实习教学中,巧妙得当的借力于网络资源平台,有助于打破临床师资缺乏、实操场地不足的局限,能更充分的发挥PBL教学的优势。此模式在培养和锻炼医学生临床思维能力的同时,也帮助他们尽早养成主动学习、善于协作、乐于共享的良好学习习惯,提高其医学人文素养。     

脊髓型颈椎病手术治疗新进展

颈椎病是指因颈椎间盘退行性变及其继发改变所导致的脊髓、神经、血管等结构受压而表现出的一系列临床症状和体征,根据发病机制可分为神经根型、脊髓型、椎动脉型、交感型、混合型,以及近年来受到重视的脊髓前动脉受压症等,脊髓型颈椎病是其中一种严重类型,保守治疗效果不佳,目前临床上常用的治疗方法为手术治疗。根据患者病情手术的入路可分为前路和后路,本文分别从手术的前后入路出发,对近年来脊髓型颈椎病手术治疗方式的进展作一综述。     

Image-guided Convection-enhanced Delivery into Agarose Gel Models of the Brain

Convection-enhanced delivery (CED) has been proposed as a treatment option for a wide range of neurological diseases. Neuroinfusion catheter CED allows for positive pressure bulk flow to deliver greater quantities of therapeutics to an intracranial target than traditional drug delivery methods. The clinical utility of real time MRI guided CED (rCED) lies in the ability to accurately target, monitor therapy, and identify complications. With training, rCED is efficient and complications may be minimized. The agarose gel model of the brain provides an accessible tool for CED testing, research, and training. Simulated brain rCED allows practice of the mock surgery while also providing visual feedback of the infusion. Analysis of infusion allows for calculation of the distribution fraction (Vd/Vi) allowing the trainee to verify the similarity of the model as compared to human brain tissue. This article describes our agarose gel brain phantom and outlines important metrics during a CED infusion and analysis protocols while addressing common pitfalls faced during CED infusion for the treatment of neurological disease.     

神经外科重症监护病房耐万古霉素肠球菌感染的流行特征及危险因素研究

目的:探讨神经外科重症监护病房(ICU)耐万古霉素肠球菌(VRE)感染的流行特征及危险因素,为临床防控提供参考依据。方法:选择2014年1月至2016年1月在我院接受手术治疗的神经外科ICU住院患者420例为研究对象。比较VRE感染患者在感染前抗生素的应用情况,并分别应用单因素及多因素Logistic回归分析分析VRE感染患者的危险因素,提出防控措施。结果:420例ICU住院患者中,VRE感染者58例,占13.81%。VRE感染患者在感染前应用的抗生素以三代头孢最多,占37.93%,以四代头孢最少,占6.90%。由单因素及多因素Logistic回归分析显示,ICU住院时间≥14 d、留置尿管≥14 d、格拉斯哥昏迷量表(GCS)评分8分以及附近存在VRE感染者均为VRE感染患者的危险因素(P0.05)。结论:VRE感染患者在感染前应用的抗生素以三代头孢最多,ICU住院时间14 d、留置尿管14 d、GCS评分8分以及附近存在VRE感染者均为VRE感染患者的危险因素,临床上应合理应用抗生素,采取相应的防控措施,降低VRE感染的发生。     

Clinical Features of Brain Metastases in Small Cell Lung Cancer: an Implication for Hippocampal Sparing Whole Brain Radiation Therapy

PURPOSE: To assess the clinical features and distribution of brain metastases (BMs) of small cell lung cancer (SCLC) in the hippocampal and perihippocampal region, with the purpose of exploring the viability of hippocampal-sparing whole-brain radiation therapy (HS-WBRT) on reducing neurocognitive deficits. METHODS: This was a retrospective analysis of the clinical characteristics and patterns of BMs in patients with SCLC. Associations between the clinical characteristics and hippocampal metastases (HMs)/perihippocampal metastases (PHMs) were evaluated in univariate and multivariate regression analyses. RESULTS: A total of 1594 brain metastatic lesions were identified in 180 patients. Thirty-two (17.8%) patients were diagnosed with BMs at the time of primary SCLC diagnosis. The median interval between diagnosis of primary SCLC and BMs was 9.3 months. There were 9 (5.0%) and 22 (12.2%) patients with HMs and PHMs (patients with BMs located in or within 5 mm around the hippocampus), respectively. In the univariate and multivariate analysis, the number of BMs was the risk factor for HMs and PHMs. Patients with BMs ≥ 5 had significantly higher risk of HMs (odds ratio [OR] 7.892, 95% confidence interval [CI] 1.469-42.404, P = .016), and patients with BMs ≥ 7 had significantly higher risk of PHMs (OR 5.162, 95% CI 2.017-13.213, P = .001). Patients with extracranial metastases are also associated with HMs. CONCLUSIONS: Our results indicate that patients with nonoligometastatic disease are significantly associated with HMs and PHMs. The incidence of PHMs may be acceptably low enough to perform HS-WBRT for SCLC. Our findings provide valuable clinical data to assess the benefit of HS-WBRT in SCLC patients with BMs.     

Long-term survival results after treatment for oligometastatic brain disease

AimThe aim of this study was to characterize the survival results of patients with up to four brain metastases after intense local therapy (primary surgery or stereotactic radiotherapy) if extracranial metastases were absent or limited to one site, e.g. the lungs.BackgroundOligometastatic disease has repeatedly been reported to convey a favorable prognosis.Material and methodsThis retrospective study included 198 German and Norwegian patients treated with individualized approaches, always including brain radiotherapy. Information about age, extracranial spread, number of brain metastases, performance status and other variables was collected. Uni- and multivariate tests were performed.ResultsMedian survival was 16.5 months (single brain metastasis) and 9.8 months (2–4, comparable survival for 2, 3 and 4), respectively (p = 0.001). After 5 years, 15 and 2% of the patients were still alive. In patients alive after 2 years, added median survival was 23 months and the probability of being alive 5 years after treatment was 26%. In multivariate analysis, extracranial metastases were not significantly associated with survival, while primary tumor control was.ConclusionLong-term survival beyond 5 years is possible in a minority of patients with oligometastatic brain disease, in particular those with a single brain metastasis. The presence of extracranial metastases to one site should not be regarded a barrier towards maximum brain-directed therapy.     

Evidence-based methodology for obtaining commercial insurance coverage of stereotactic radiosurgery for intractable epilepsy

ObjectivesThe coverage policies of many commercial insurers in the United States do not include coverage of stereotactic radiosurgery (SRS) for intractable epilepsy despite recent Level I evidence supporting its efficacy. We sought to assess the efficacy of an evidence-based methodology in obtaining coverage approval of SRS for intractable epilepsy.Patients and MethodsThe clinical policy guidelines from five of the largest United States commercial insurers were reviewed for their language regarding coverage of SRS for epilepsy. An evidence-based questionnaire was created for temporal lobe epilepsy and extratemporal lobe epilepsy based on recent evidence. Telephone interviewers of Insurers assessed the likelihood of SRS coverage for an epilepsy patient meeting the clinical inclusion criteria in the questionnaire. This likelihood was assessed numerically based on interviewee response (2 = yes, 1 = dependent on peer-to-peer, 0 = no).ResultsOf the five policy guidelines, none included literature more recent than 2017. For TLE, 3/5 insurance companies indicated likely SRS coverage; 2/5 indicated peer-to-peer discussion dependence for patients meeting questionnaire criteria for a score of 8/10. For extratemporal TLE, 2/5 companies indicated likely SRS coverage and 3/5 indicated peer-to-peer discussion dependence for a total score of 7/10.ConclusionCreation of an evidence-based methodology in approaching commercial insurers greatly increased the likelihood of SRS coverage for an indication (intractable epilepsy) widely perceived as investigational. These results should pave the way for epilepsy patients to receive coverage should they be appropriate SRS candidates.